Axonics Modulation Technologies Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axonics Modulation Technologies stock.
View analyst ratings for Axonics Modulation Technologies or view top-rated stocks.

Wall Street analysts have given Axonics Modulation Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axonics Modulation Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Axonics Modulation Technologies is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Axonics Modulation Technologies.

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) posted its earnings results on Monday, November, 9th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.28. The business earned $35.24 million during the quarter, compared to analyst estimates of $22.95 million. Axonics Modulation Technologies had a negative net margin of 76.62% and a negative trailing twelve-month return on equity of 28.05%. Axonics Modulation Technologies's revenue was up 2592.4% on a year-over-year basis. During the same period last year, the firm earned ($0.89) EPS.
View Axonics Modulation Technologies' earnings history.

Axonics Modulation Technologies' stock was trading at $30.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXNX stock has increased by 75.0% and is now trading at $52.87.
View which stocks have been most impacted by COVID-19.

Axonics Modulation Technologies issued an update on its FY 2020 After-Hours earnings guidance on Monday, January, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $111.5-111.5 million, compared to the consensus revenue estimate of $112.31 million.

8 analysts have issued 12 month price targets for Axonics Modulation Technologies' stock. Their forecasts range from $48.00 to $77.00. On average, they expect Axonics Modulation Technologies' share price to reach $61.00 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Axonics Modulation Technologies or view top-rated stocks among Wall Street analysts.

12 employees have rated Axonics Modulation Technologies CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics Modulation Technologies' employees.

Some companies that are related to Axonics Modulation Technologies include Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), Nevro (NVRO), Tandem Diabetes Care (TNDM), Inari Medical (NARI), ICU Medical (ICUI), iRhythm Technologies (IRTC), Glaukos (GKOS), ShockWave Medical (SWAV), Merit Medical Systems (MMSI), Cantel Medical (CMD) and NuVasive (NUVA).
View all of AXNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

Axonics Modulation Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include Credit Suisse AG (6.36%), BlackRock Inc. (5.73%), Lord Abbett & CO. LLC (3.82%), Bamco Inc. NY (3.22%), Hood River Capital Management LLC (1.32%) and Peregrine Capital Management LLC (1.18%). Company insiders that own Axonics Modulation Technologies stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics Modulation Technologies.

AXNX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Parian Global Management LP, Calamos Advisors LLC, Russell Investments Group Ltd., Kennedy Capital Management Inc., Peregrine Capital Management LLC, Castleark Management LLC, and Northern Trust Corp. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics Modulation Technologies or view top insider-selling stocks.

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Credit Suisse AG, Hood River Capital Management LLC, Lord Abbett & CO. LLC, Columbus Circle Investors, Oak Ridge Investments LLC, Armistice Capital LLC, Magnetar Financial LLC, and Tri Locum Partners LP. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Nancy Lynn Md Snyderman, and Raymond W Cohen.
View insider buying and selling activity for Axonics Modulation Technologies or or view top insider-buying stocks.

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXNX stock can currently be purchased for approximately $52.87.

Axonics Modulation Technologies has a market capitalization of $2.10 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

Axonics Modulation Technologies employs 302 workers across the globe.

The official website for Axonics Modulation Technologies is www.axonics.com.

Axonics Modulation Technologies is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322 or via email at [email protected]